JPWO2019224467A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019224467A5 JPWO2019224467A5 JP2020565372A JP2020565372A JPWO2019224467A5 JP WO2019224467 A5 JPWO2019224467 A5 JP WO2019224467A5 JP 2020565372 A JP2020565372 A JP 2020565372A JP 2020565372 A JP2020565372 A JP 2020565372A JP WO2019224467 A5 JPWO2019224467 A5 JP WO2019224467A5
- Authority
- JP
- Japan
- Prior art keywords
- microcompartment
- cells
- bioreactor
- cell
- culture system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 247
- 239000000017 hydrogel Substances 0.000 claims description 65
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 46
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 46
- 210000002744 extracellular matrix Anatomy 0.000 claims description 46
- 238000004113 cell culture Methods 0.000 claims description 31
- 210000000130 stem cell Anatomy 0.000 claims description 31
- 238000004519 manufacturing process Methods 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 28
- 210000002220 organoid Anatomy 0.000 claims description 24
- 230000008569 process Effects 0.000 claims description 18
- 230000001413 cellular effect Effects 0.000 claims description 14
- 208000031513 cyst Diseases 0.000 claims description 11
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 11
- 238000012258 culturing Methods 0.000 claims description 10
- 238000009792 diffusion process Methods 0.000 claims description 9
- 230000035755 proliferation Effects 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 230000003301 hydrolyzing effect Effects 0.000 claims description 4
- 230000024245 cell differentiation Effects 0.000 claims description 3
- 230000010412 perfusion Effects 0.000 claims description 3
- 239000002609 medium Substances 0.000 description 49
- 239000002775 capsule Substances 0.000 description 25
- 230000004069 differentiation Effects 0.000 description 13
- 230000003321 amplification Effects 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 238000003199 nucleic acid amplification method Methods 0.000 description 12
- 230000037361 pathway Effects 0.000 description 12
- 210000001671 embryonic stem cell Anatomy 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 239000011435 rock Substances 0.000 description 9
- 239000013589 supplement Substances 0.000 description 9
- 230000035800 maturation Effects 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 5
- 206010011732 Cyst Diseases 0.000 description 5
- 229940072056 alginate Drugs 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 229920000615 alginic acid Polymers 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000005538 encapsulation Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 210000001808 exosome Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 230000008672 reprogramming Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- CDOVNWNANFFLFJ-UHFFFAOYSA-N 4-[6-[4-(1-piperazinyl)phenyl]-3-pyrazolo[1,5-a]pyrimidinyl]quinoline Chemical compound C1CNCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CC=C3N=CC=2)C=C1 CDOVNWNANFFLFJ-UHFFFAOYSA-N 0.000 description 3
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 108010085895 Laminin Proteins 0.000 description 3
- 102000007547 Laminin Human genes 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000003291 dopaminomimetic effect Effects 0.000 description 3
- 210000001900 endoderm Anatomy 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- OSENKJZWYQXHBN-XVYZBDJZSA-N 24(S),25-epoxycholesterol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2CC1)C)C[C@@H]1OC1(C)C OSENKJZWYQXHBN-XVYZBDJZSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000037416 cystogenesis Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WCAWZARVUUEHRX-FRKDHNBESA-N (2e,4e,6r)-7-[4-(dimethylamino)phenyl]-n-hydroxy-6-methyl-7-oxohepta-2,4-dienamide Chemical compound ONC(=O)/C=C/C=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 WCAWZARVUUEHRX-FRKDHNBESA-N 0.000 description 1
- AEMOLEFTQBMNLQ-SYJWYVCOSA-N (2s,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-SYJWYVCOSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical group CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 102100031361 Fibroblast growth factor 20 Human genes 0.000 description 1
- 108050002085 Fibroblast growth factor 20 Proteins 0.000 description 1
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 101001027382 Homo sapiens Fibroblast growth factor 8 Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100037369 Nidogen-1 Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000002032 lab-on-a-chip Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 108010008217 nidogen Proteins 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- FYBHCRQFSFYWPY-UHFFFAOYSA-N purmorphamine Chemical compound C1CCCCC1N1C2=NC(OC=3C4=CC=CC=C4C=CC=3)=NC(NC=3C=CC(=CC=3)N3CCOCC3)=C2N=C1 FYBHCRQFSFYWPY-UHFFFAOYSA-N 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 229940006186 sodium polystyrene sulfonate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 229940121396 wnt pathway inhibitor Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025092385A JP2025128230A (ja) | 2018-05-21 | 2025-06-03 | バイオリアクターにおける細胞培養のためのシステム |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1854207A FR3081168B1 (fr) | 2018-05-21 | 2018-05-21 | Systeme de culture cellulaire en bioreacteur |
| FR1854207 | 2018-05-21 | ||
| PCT/FR2019/051144 WO2019224467A1 (fr) | 2018-05-21 | 2019-05-20 | Système de culture cellulaire en bioréacteur |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025092385A Division JP2025128230A (ja) | 2018-05-21 | 2025-06-03 | バイオリアクターにおける細胞培養のためのシステム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021524253A JP2021524253A (ja) | 2021-09-13 |
| JP2021524253A5 JP2021524253A5 (https=) | 2022-05-27 |
| JPWO2019224467A5 true JPWO2019224467A5 (https=) | 2022-05-27 |
Family
ID=64049308
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565372A Pending JP2021524253A (ja) | 2018-05-21 | 2019-05-20 | バイオリアクターでの細胞培養システム |
| JP2025092385A Pending JP2025128230A (ja) | 2018-05-21 | 2025-06-03 | バイオリアクターにおける細胞培養のためのシステム |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025092385A Pending JP2025128230A (ja) | 2018-05-21 | 2025-06-03 | バイオリアクターにおける細胞培養のためのシステム |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20210123013A1 (https=) |
| EP (1) | EP3797150A1 (https=) |
| JP (2) | JP2021524253A (https=) |
| KR (2) | KR20210011975A (https=) |
| CN (1) | CN112424333A (https=) |
| AU (1) | AU2019273006B2 (https=) |
| BR (1) | BR112020023707A2 (https=) |
| CA (1) | CA3101003A1 (https=) |
| CL (1) | CL2020003003A1 (https=) |
| FR (1) | FR3081168B1 (https=) |
| IL (2) | IL325018A (https=) |
| MX (1) | MX2020012412A (https=) |
| SG (1) | SG11202011501XA (https=) |
| WO (1) | WO2019224467A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3122883A1 (fr) * | 2021-05-11 | 2022-11-18 | Treefrog Therapeutics | Microcompartiments cellulaires comprenant des cellules dont l’intégrité génomique est maintenue après amplification et procédé de préparation |
| CN114214267B (zh) * | 2021-12-06 | 2024-04-09 | 大连大学 | 一种类器官基质胶微球及其制备方法和应用 |
| CN114672455B (zh) * | 2022-03-25 | 2024-07-09 | 中山大学 | 一种利用多能干细胞诱导骨髓基质细胞的方法 |
| US20250213470A1 (en) | 2022-06-03 | 2025-07-03 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods |
| FR3151044B1 (fr) * | 2023-07-11 | 2026-04-24 | Treefrog Therapeutics | Transduction et/ou transfection dans un microcompartiment en trois dimensions |
| WO2025211257A1 (ja) * | 2024-04-01 | 2025-10-09 | 慶應義塾 | オルガノイド製造用培地及びその使用 |
| CN118308295B (zh) * | 2024-06-06 | 2024-08-27 | 上海遇见味来生物技术有限公司 | 一种促进细胞生产胶原的添加剂、培养基及方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004260106C1 (en) * | 2003-07-17 | 2010-12-09 | Global Cell Solutions, Llc. | Automated cell culture system and process |
| DE10349484A1 (de) * | 2003-10-21 | 2005-05-25 | Universität Leipzig | Verfahren und Bioreaktor zum Kultivieren und Stimulieren von dreidimensionalen, vitalen und mechanisch widerstandsfähigen Zelltransplantaten |
| JP2006136212A (ja) * | 2004-11-10 | 2006-06-01 | Olympus Corp | 細胞培養用担体 |
| CN1288235C (zh) * | 2004-11-25 | 2006-12-06 | 西安交通大学 | 一种旋转灌注式生物反应器系统 |
| US9109193B2 (en) * | 2007-07-30 | 2015-08-18 | Ge Healthcare Bio-Sciences Corp. | Continuous perfusion bioreactor system |
| JP2009247334A (ja) * | 2008-04-11 | 2009-10-29 | Toray Ind Inc | 細胞培養担体 |
| ES2579909T3 (es) * | 2009-02-03 | 2016-08-17 | Koninklijke Nederlandse Akademie Van Wetenschappen | Medio de cultivo para células madre epiteliales y organoides que comprenden dichas células madre |
| CN102405280B (zh) | 2009-03-20 | 2015-03-04 | 中胚层公司 | 重新设定的多能干细胞的制备 |
| EP2718416B1 (en) * | 2011-06-06 | 2019-11-13 | Regenesys bvba | Expansion of stem cells in hollow fiber bioreactors |
| CN103146572B (zh) * | 2011-12-07 | 2016-01-06 | 清华大学 | 一种实现细胞集落均质性生长的装置和方法 |
| EP2902478A1 (en) * | 2012-09-06 | 2015-08-05 | Pluristem Ltd. | Devices and methods for culture of cells |
| US11583860B2 (en) * | 2014-12-22 | 2023-02-21 | Ecole Polytechnique Federale De Lausanne (Epfl) | Microstructured thin hydrogel films |
| JP6807853B2 (ja) * | 2015-03-03 | 2021-01-06 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 機能的ヒト組織の作製方法 |
| EP3296018A1 (en) * | 2016-09-19 | 2018-03-21 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Organoid arrays |
| GB201706544D0 (en) * | 2017-04-25 | 2017-06-07 | Plasticell Ltd | Method |
-
2018
- 2018-05-21 FR FR1854207A patent/FR3081168B1/fr active Active
-
2019
- 2019-05-20 KR KR1020207036522A patent/KR20210011975A/ko not_active Ceased
- 2019-05-20 KR KR1020257009299A patent/KR20250044479A/ko not_active Ceased
- 2019-05-20 CA CA3101003A patent/CA3101003A1/fr active Pending
- 2019-05-20 IL IL325018A patent/IL325018A/en unknown
- 2019-05-20 CN CN201980034566.7A patent/CN112424333A/zh active Pending
- 2019-05-20 AU AU2019273006A patent/AU2019273006B2/en active Active
- 2019-05-20 US US17/057,143 patent/US20210123013A1/en active Pending
- 2019-05-20 SG SG11202011501XA patent/SG11202011501XA/en unknown
- 2019-05-20 JP JP2020565372A patent/JP2021524253A/ja active Pending
- 2019-05-20 EP EP19733852.8A patent/EP3797150A1/fr active Pending
- 2019-05-20 WO PCT/FR2019/051144 patent/WO2019224467A1/fr not_active Ceased
- 2019-05-20 BR BR112020023707-8A patent/BR112020023707A2/pt active Search and Examination
- 2019-05-20 MX MX2020012412A patent/MX2020012412A/es unknown
-
2020
- 2020-11-17 IL IL278775A patent/IL278775B1/en unknown
- 2020-11-18 CL CL2020003003A patent/CL2020003003A1/es unknown
-
2025
- 2025-06-03 JP JP2025092385A patent/JP2025128230A/ja active Pending
- 2025-06-10 US US19/233,809 patent/US20250304909A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025128230A (ja) | バイオリアクターにおける細胞培養のためのシステム | |
| US12146153B2 (en) | Cellular microcompartment and preparation processes | |
| CN112195152B (zh) | 一种人结直肠癌组织类器官的培养方法及其应用 | |
| JP2018534936A (ja) | 大規模細胞製造システム | |
| CN103351484A (zh) | 一种微图案化水凝胶涂层及其制备方法与用途 | |
| KR20240004941A (ko) | 증폭 및 제조 방법 후에 게놈 완전성이 유지되는 셀을 포함하는 셀형 미세구획 | |
| JP7541986B2 (ja) | 三次元マトリックスなしでのヒト多能性幹細胞由来人工組織構造体の生成 | |
| US20240043793A1 (en) | Extracellular matrix substitute in a cellular microcompartment | |
| Zhao et al. | Application of stem cells in engineered vascular graft and vascularized organs | |
| JP2025528743A (ja) | 細胞微小区画における細胞外マトリックス代替物 | |
| KR20250125982A (ko) | 세포 미세구획의 세포외 기질 대체물 | |
| JPWO2019224467A5 (https=) | ||
| CN112852709B (zh) | 小鼠肺类器官培养方法 | |
| KR20240032739A (ko) | 복수의 낭종을 포함하는 큰 세포 미세구획 | |
| CN117286106B (zh) | 一种小鼠视网膜类器官的构建方法 | |
| CN116606802A (zh) | 一种心肌纤维化三维细胞模型的建立方法 | |
| WO2005121319A1 (en) | Methods for production of mesodermal lineage cells | |
| CN116004540A (zh) | 一种基于海藻酸钠冷冻凝胶支架的肺肿瘤类器官模型 | |
| KR20250172953A (ko) | 조성물 | |
| Borozenets et al. | Features of spheroidogenesis of L929 cell line during prolonged three-dimensional cultivation | |
| KR20250052833A (ko) | 간독성 평가 시스템 | |
| RU2563347C2 (ru) | Способ культивирования стволовых клеток, препятствующий их спонтанной дифференцировке (варианты) | |
| NZ794660A (en) | Cellular microcompartment and preparation methods |